Lipella Pharmaceuticals (Lipella Pharmaceuticals) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lipella Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2024 was $-1.39 Mil. Lipella Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Lipella Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Lipella Pharmaceuticals's current FCF Yield % is -69.51%.

The historical rank and industry rank for Lipella Pharmaceuticals's FCF Margin % or its related term are showing as below:

LIPO' s FCF Margin % Range Over the Past 10 Years
Min: -995.11 Med: -542.48 Max: -3.01
Current: -768.89

During the past 4 years, the highest FCF Margin % of Lipella Pharmaceuticals was -3.01%. The lowest was -995.11%. And the median was -542.48%.

LIPO's FCF Margin % is ranked worse than
72.15% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs LIPO: -768.89

Lipella Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Lipella Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals FCF Margin % Chart

Lipella Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-3.01

-381.85

-995.11

-703.11

Lipella Pharmaceuticals Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial									-	-	-	-161.78	-

Competitive Comparison of Lipella Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Lipella Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipella Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's FCF Margin % falls into.

Lipella Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lipella Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3.164	/	0.45
	=	-703.11 %

Lipella Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.388	/	0
	=	%

Lipella Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208

Website

https://www.lipella.com

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.

Executives

Lori Birder	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman	director, 10 percent owner, officer: See Remarks	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston	officer: Chief Financial Officer	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor	director, 10 percent owner, officer: Chief Medical Officer	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208